The Latest Analyst Ratings for Gracell Biotechnologies
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Gracell Biotechnologies (NASDAQ:GRCL) within the last quarter, with an average price target of $15.0 versus the current price of $2.67. This current average has increased by 25.0% from the previous average price target of $12.00.
October 19, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bullish analyst ratings and a significant increase in the average price target suggest a positive outlook for Gracell Biotechnologies.
Analysts have provided bullish ratings for Gracell Biotechnologies and raised the average price target by 25.0% to $15.0. This suggests a positive outlook for the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100